amodiaquine has been researched along with Icterus in 1 studies
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.
amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It is recommended that children aged 3 months to five years of age living in areas of seasonal transmission in the sub-Sahel should receive Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) during the malaria transmission season." | 9.22 | Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial. ( Ba, EH; Cairns, M; Cissé, B; Fall, FB; Faye, B; Gaye, O; Gomis, JF; Greenwood, BM; Kouevijdin, E; Milligan, PJ; Molez, JF; NDiaye, JL; Ndour, CT; Niane, FK; Rogier, C; Sokhna, C; Trape, JF, 2016) |
| "It is recommended that children aged 3 months to five years of age living in areas of seasonal transmission in the sub-Sahel should receive Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) during the malaria transmission season." | 5.22 | Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial. ( Ba, EH; Cairns, M; Cissé, B; Fall, FB; Faye, B; Gaye, O; Gomis, JF; Greenwood, BM; Kouevijdin, E; Milligan, PJ; Molez, JF; NDiaye, JL; Ndour, CT; Niane, FK; Rogier, C; Sokhna, C; Trape, JF, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| NDiaye, JL | 1 |
| Cissé, B | 1 |
| Ba, EH | 1 |
| Gomis, JF | 1 |
| Ndour, CT | 1 |
| Molez, JF | 1 |
| Fall, FB | 1 |
| Sokhna, C | 1 |
| Faye, B | 1 |
| Kouevijdin, E | 1 |
| Niane, FK | 1 |
| Cairns, M | 1 |
| Trape, JF | 1 |
| Rogier, C | 1 |
| Gaye, O | 1 |
| Greenwood, BM | 1 |
| Milligan, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Public Health Impact and Cost Effectiveness of Seasonal Intermittent Preventive Treatment in Children in Senegal[NCT00712374] | Phase 4 | 100,000 participants (Anticipated) | Interventional | 2008-09-30 | Enrolling by invitation | ||
| A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined[NCT03143218] | Phase 3 | 5,920 participants (Actual) | Interventional | 2017-04-17 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Passive surveillance to detect episode of fever (temperature > 37.5 C), or a history of fever within the past 48 hours, that is severe enough to require treatment at a health centre and which is accompanied by a positive blood film with a parasite density of 5,000 per µl or more (NCT03143218)
Timeframe: Passive surveillance of clinical episodes of malaria within the study area starting from the date of the first dose of study vaccines (April/May 2017) until 31st March 2020- a total of 36 months.
| Intervention | No. of events/1000 person years at risk (Number) |
|---|---|
| SMC With SP+AQ | 304.8 |
| RTS,S/AS01 | 278.2 |
| RTS,S/AS01 PLUS SMC With SP+AQ | 113.3 |
1 trial available for amodiaquine and Icterus